


# Low-cost drug Heparin effective and safe treatment for COVID-19

January 21 2022



Activated partial thromboplastin time (APTT) levels before (baseline) and highest levels during (peak) inhaled nebulised unfractionated heparin treatment. Panel A: baseline and peak APTT levels in patients who received concomitant therapeutic heparin infusion (UFH therapeutic) or who did not receive concomitant therapeutic heparin infusion (no UFH therapeutic). Panel B: baseline and peak APTT levels for each inhaled nebulised UFH treatment dose

group. Data shown as mean  $\pm$  standard deviation, \*\*\* P

Citation: Low-cost drug Heparin effective and safe treatment for COVID-19 (2022, January 21)  
retrieved 26 April 2024 from

<https://medicalxpress.com/news/2022-01-low-cost-drug-heparin-effective-safe.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.